In many cases, the end of the year gives you time to step back and take stock of the last 12 months. This is when many of us take a hard look at what worked and what did not, complete performance reviews, and formulate plans for the coming year. For me, it is all of those things plus a time when I u...

We are reverting to a Neutral recommendation on Bayer (OTC:BAYRY) as we believe that all the positive news that led to our previous Outperform recommendation on the stock are reflected in the current price.

Bayer performed impressively in the third quarter of 2012, driven by an increase in revenues. Bayer's earnings per share during the third quarter of 2012 came in at €1.68 compared with €1.12 in the year-ago period. The company recorded 11.5% growth in revenues to €9,665 million. Growth was witnessed across all the major divisions at Bayer.

Bayer continues to expect 2012 earnings to increase by 10% year over year. Blood-thinner Xarelto, which has significant commercial potential, performed well during the quarter. The HealthCare unit of Bayer has co-developed Xarelto with Johnson & Johnson (NYSE:JNJ).

We are also impressed by the US approval of Stivarga for use in treatment-experienced metastatic colorectal cancer patients. Bayer is also looking to get Stivarga approved for treating patients suffering from metastatic and/or unresectable gastrointestinal stromal tumors (GIST). The US Food and Drug Administration (FDA) is reviewing the marketing application seeking approval of Stivarga for the GIST indication on a priority basis. Bayer is also seeking Japanese approval of Stivarga for the GIST indication. The sales potential of Stivarga would be further boosted if the regulatory authorities clear the drug for the GIST indication.

We are also positive on the European approval of eye-drug Eylea for treating patients suffering from neovascular (wet) age-related macular degeneration (wet AMD). Bayer is also seeking to expand the label of Eylea into other eye disorders. The HealthCare unit of Bayer has co-developed Eylea with Regeneron Pharmaceuticals (Nasdaq:REGN).

However, we are mindful of the regulatory/pipeline setbacks at Bayer. In August 2012, Bayer and partner Sanofi (NYSE:SNY) suffered a setback when the FDA issued a refuse-to-file letter regarding the marketing application submitted in June 2012, seeking approval to market Lemtrada for the treatment of relapsing multiple sclerosis.

Apart from this regulatory setback, Bayer suffered a pipeline setback in May 2012 when Nexavar (sorafenib), co-developed with Onyx Pharmaceuticals Inc. (Nasdaq:ONXX), failed to prolong the overall survival in patients suffering from advanced non-squamous non-small cell lung cancer in a phase III study.

Moreover, the generic threat looming over many of Bayer's key products including the Yaz franchise (oral contraceptives) is another challenge for the company.

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leon Zacks. As a PhD from MIT Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=5518.

Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.

"We've just seen a huge influx of new partners coming into our ecosystem, and partners building unique offerings on top of our API set," explained Seth Bostock, Chief Executive Officer at IndependenceIT, in this SYS-CON.tv interview at 16th Cloud Expo, held June 9-11, 2015, at the Javi...

SYS-CON Events announced today that HPM Networks will exhibit at the 17th International Cloud Expo®, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA.
For 20 years, HPM Networks has been integrating technology solutions that solve co...

The Software Defined Data Center (SDDC), which enables organizations to seamlessly run in a hybrid cloud model (public + private cloud), is here to stay. IDC estimates that the software-defined networking market will be valued at $3.7 billion by 2016.
Security is a key component and b...

Learn how to solve the problem of keeping files in sync between multiple Docker containers.
In his session at 16th Cloud Expo, Aaron Brongersma, Senior Infrastructure Engineer at Modulus, discussed using rsync, GlusterFS, EBS and Bit Torrent Sync. He broke down the tools that are need...

Explosive growth in connected devices. Enormous amounts of data for collection and analysis. Critical use of data for split-second decision making and actionable information. All three are factors in making the Internet of Things a reality. Yet, any one factor would have an IT organiza...

Public Cloud IaaS started its life in the developer and startup communities and has grown rapidly to a $20B+ industry, but it still pales in comparison to how much is spent worldwide on IT: $3.6 trillion. In fact, there are 8.6 million data centers worldwide, the reality is many small...